Investigating Bone and Skeletal Muscle Interaction in Men With Prostate Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 55 - 89 |
| Updated: | 5/4/2018 |
| Start Date: | October 1, 2017 |
| End Date: | December 31, 2018 |
| Contact: | Craig Principal investigator, MD |
| Email: | craig.rubin@utsouthwestern.edu |
| Phone: | 2146489012 |
Investigating Bone and Skeletal Muscle Interaction in Men With Prostate Cancer Treated With Androgen Deprivation Therapy.
The overall goal of this pilot project is to test the hypothesis that a decline in muscle
strength precedes the decline in bone strength in men undergoing androgen deprivation therapy
(ADT) for prostate cancer. The investigators will measure changes in serum biomarkers
involved in muscle-bone crosstalk, anatomic changes in muscle and bone structure and strength
that could ultimately contribute to fractures. The findings from this research will inform
design of interventions to reduce falls and hip fractures in patients undergoing ADT as well
as application to broader populations of at risk patients.
strength precedes the decline in bone strength in men undergoing androgen deprivation therapy
(ADT) for prostate cancer. The investigators will measure changes in serum biomarkers
involved in muscle-bone crosstalk, anatomic changes in muscle and bone structure and strength
that could ultimately contribute to fractures. The findings from this research will inform
design of interventions to reduce falls and hip fractures in patients undergoing ADT as well
as application to broader populations of at risk patients.
Twenty-five men from urology clinic with prostate cancer will be recruited and enrolled prior
to initiating ADT and studied at three time points. Baseline (before first does of ADT), and
at approximately weeks 6 and 24 while receiving ADT for prostate cancer. Study measures will
be the same during each of three data acquisition time points and include ascertainment of
venous blood to determine serum biochemical markers of muscle and bone metabolic activity,
MRI and CT imaging studies to assess muscle strength, volume, composition, bone volume,
density and strength, and validated tests of muscle strength. Subjects will serve as their
own controls.
to initiating ADT and studied at three time points. Baseline (before first does of ADT), and
at approximately weeks 6 and 24 while receiving ADT for prostate cancer. Study measures will
be the same during each of three data acquisition time points and include ascertainment of
venous blood to determine serum biochemical markers of muscle and bone metabolic activity,
MRI and CT imaging studies to assess muscle strength, volume, composition, bone volume,
density and strength, and validated tests of muscle strength. Subjects will serve as their
own controls.
Inclusion Criteria:
• Dx with prostate cancer and planned ADT therapy
Exclusion Criteria:
- Contraindication to MRI
- Limited life expectancy
- Inability to participate in exercise testing
- Severe functional impairment
- Chronic kidney disease 4 or worse
- Hgb < 9
- Use of anti-resorptive agent
- non-English speaking
- Bone metastasis
We found this trial at
1
site
Click here to add this to my saved trials
